$766 Million is the total value of Opaleye Management Inc.'s 59 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 82.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | Buy | OCULAR THERAPEUTIX INC | $134,758,000 | +195.9% | 6,510,000 | +8.8% | 17.60% | +97.6% |
| ETON | Buy | ETON PHARMACEUTICALS INC | $32,845,000 | +14.2% | 4,040,000 | +11.0% | 4.29% | -23.7% |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $29,465,000 | +183.1% | 2,518,371 | +25.1% | 3.85% | +89.0% |
| HROW | Buy | HARROW HEALTH INC | $21,029,000 | +27.1% | 3,065,416 | +3.6% | 2.75% | -15.1% |
| CMRX | Buy | CHIMERIX INC | $19,110,000 | +99.8% | 3,956,500 | +3.0% | 2.50% | +33.4% |
| FBIO | Buy | FORTRESS BIOTECH INC | $12,323,000 | +20.1% | 3,887,500 | +1.5% | 1.61% | -19.8% |
| CYTK | Buy | CYTOKINETICS INC | $12,111,000 | +167.9% | 582,800 | +179.1% | 1.58% | +79.0% |
| LUMO | Buy | LUMOS PHARMA INC | $10,045,000 | +201.7% | 281,287 | +16.8% | 1.31% | +101.5% |
| PCVX | Buy | VAXCYTE | $8,906,000 | -42.4% | 335,200 | +7.1% | 1.16% | -61.5% |
| FSDC | New | FS DEV CORP | $7,748,000 | – | 704,400 | +100.0% | 1.01% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $7,020,000 | – | 260,000 | +100.0% | 0.92% | – |
| STRO | Buy | SUTRO BIOPHARMA INC | $6,995,000 | +376.8% | 322,200 | +120.7% | 0.91% | +218.5% |
| TCDA | New | TRICIDA INC | $6,761,000 | – | 959,000 | +100.0% | 0.88% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $6,496,000 | – | 381,900 | +100.0% | 0.85% | – |
| MRUS | Buy | MERUS NV | $6,188,000 | +309300.0% | 353,000 | +176400.0% | 0.81% | – |
| SIOX | New | SIO GENE THERAPIES INC | $5,560,000 | – | 2,000,000 | +100.0% | 0.73% | – |
| TELA | Buy | TELA BIO INC | $5,490,000 | -8.3% | 365,000 | +0.8% | 0.72% | -38.8% |
| VSTM | Buy | VERASTEM INC | $4,761,000 | +48.7% | 2,325,000 | +5.7% | 0.62% | -0.6% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $3,696,000 | +12.6% | 708,000 | +4.4% | 0.48% | -24.8% |
| PRAX | New | PRAXIS PRECISION MEDICINES INC | $3,489,000 | – | 63,416 | +100.0% | 0.46% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $3,419,000 | – | 115,000 | +100.0% | 0.45% | – |
| EPIX | Buy | ESSA PHARMA INC | $3,389,000 | +81.0% | 284,050 | +4.7% | 0.44% | +21.0% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $3,211,000 | +227.0% | 254,000 | +154.0% | 0.42% | +118.2% |
| CFRX | Buy | CONTRAFECT CORP | $2,222,000 | +86.1% | 440,000 | +94.6% | 0.29% | +23.9% |
| OPTN | New | OPTINOSE INC | $1,801,000 | – | 435,000 | +100.0% | 0.24% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $1,208,000 | – | 75,379 | +100.0% | 0.16% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $939,000 | – | 148,800 | +100.0% | 0.12% | – |
| AKUS | New | AKOUS INC | $901,000 | – | 45,459 | +100.0% | 0.12% | – |
| New | CATABASIS PHARMACEUTICALS INC | $402,000 | – | 187,750 | +100.0% | 0.05% | – | |
| MGTA | New | MAGENTA THERAPEUTICS INC | $375,000 | – | 47,804 | +100.0% | 0.05% | – |
| AVEO | New | AVEO BIOSCIENCES INC | $339,000 | – | 58,800 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.